82
Participants
Start Date
February 28, 2015
Primary Completion Date
April 30, 2018
Study Completion Date
April 30, 2018
NovoTTF-100L device
Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
Pemetrexed
Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
Cisplatin or Carboplatin
Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
Antwerp University Hospital, Thoracic Oncology, Antwerp
Goustave Roussy - Cancer Campus Grand Paris, Villejuif
Universitätsklinikum Halle (Saale), Halle
"A.S.O. SS Antonio e Biagio e Cesare Arrigo", Alessandria
Cliniche Humanitas Gavazzeni, Bergamo
Ospedale Villa Scassi, Genoa
Ospedaliera di Perugia, Perugia
Ospedaliero Universitaria Pisana, Pisa
Erasmus Mc, Rotterdam
Medical University Gdansk, Gdansk
Katedra i Klinika Onkologii Uniwersytetu Medycznegi im. Karola Marcinkowskiego w Poznaniu, Poznan
Klinika Nowotworów Pluca I Klatki Piersiowej, Warsaw
Vall d' Hebron Institute of Oncology (VHIO) Hospital Vall d'Hebron, Barcelona
NovoCure Ltd.
INDUSTRY